Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

White paper: How artificial intelligence and real-world data are reshaping orphan drug commercialization

WHITE PAPER

For the millions living with a rare disease, the journey to an accurate diagnosis can take years. For commercial teams, this means patients remain hidden and opportunities to intervene are missed because traditional data sources lack the clinical depth to find these small, dispersed populations.

 

By applying longitudinal real-world lab data (RWD) to artificial intelligence (AI) models, your teams can uncover the subtle clinical signals of rare diseases long before a formal diagnosis is documented.

How artificial intelligence and real-world data are reshaping orphan drug commercialization

Download our industry report to discover how this powerful data combination empowers you to:

Learn how AI and
RWD are reshaping orphan drug commercialization

937

* indicates required

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.